These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30537258)

  • 21. Targeting of circulating Th17 cells by β-D-mannuronic acid (M2000) as a novel medication in patients with rheumatoid arthritis.
    Ahmadi H; Mahmoudi M; Gharibdoost F; Vojdanian M; Jamshidi AR; Fattahi MJ; Aghazadeh Z; Barati A; Mirshafiey A
    Inflammopharmacology; 2018 Feb; 26(1):57-65. PubMed ID: 29063487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of β-D-mannuronic acid (M2000), as a novel NSAID, on COX1 and COX2 activities and gene expression in ankylosing spondylitis patients and the murine monocyte/macrophage, J774 cell line.
    Jafarnezhad-Ansariha F; Yekaninejad MS; Jamshidi AR; Mansouri R; Vojdanian M; Mahmoudi M; Fattahi MJ; Hashemi SN; Rehm BHA; Matsuo H; Esposito E; Cuzzocrea S; Mirshafiey A
    Inflammopharmacology; 2018 Apr; 26(2):375-384. PubMed ID: 28819782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-angiogenesis effect of β-D-mannuronic acid (M2000) as a novel NSAID with immunosuppressive properties under experimental model.
    Rastegari-Pouyani M; Mostafaie A; Mansouri K; Mortazavi-Jahromi SS; Mohammadi-Motlagh HR; Mirshafiey A
    Clin Exp Pharmacol Physiol; 2018 Apr; 45(4):370-376. PubMed ID: 29266560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. β-D-Mannuronic Acid (M2000) as a Landmark in Pharmacology.
    Gaafar NAG; Razavi A; Mirshafiey A
    Curr Drug Discov Technol; 2021; 18(1):47-57. PubMed ID: 31880246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Anti-tumoral Effect of β-D-Mannuronic Acid (M2000) as a Novel NSAID on Treg Cells Frequency and MMP-2, MMP-9, CCL22 and TGFβ1 Gene Expression in Pre-surgical Breast Cancer Patients.
    Kashefi S; Ahmadi H; Omranipour R; Mahmoodzadeh H; Jafarnezhad-Ansariha F; Tofighi Zavareh F; Mirshafiey A
    Iran J Allergy Asthma Immunol; 2019 Feb; 18(1):80-90. PubMed ID: 30848576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mannuronic Acid in Low-Risk and Intermediate-1-Risk Myelodysplastic Syndromes.
    Ghaderi A; Nodehi SRS; Bakhtiari T; Aslani M; Aghazadeh Z; Matsuo H; Rehm BHA; Cuzzocrea S; Mirshafiey A
    J Clin Pharmacol; 2020 Jul; 60(7):879-888. PubMed ID: 32064621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Anti-Migraine Effects of M2000 (β-D-Mannuronic Acid) on a Patient with Rheumatoid Arthritis: Case Report.
    Vojdanian M; Ahmadi H; Jamshidi AR; Mahmoudi M; Gharibdoost F; Barati A; Mirshafiey A
    Curr Clin Pharmacol; 2017; 12(2):127-130. PubMed ID: 28578645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral administration effects of β-d-mannuronic acid (M2000) on Th17 and regulatory T cells in patients with ankylosing spondylitis.
    Fattahi MJ; Ahmadi H; Jafarnezhad-Ansariha F; Mortazavi-Jahromi SS; Rehm BHA; Cuzzocrea S; Matsuo H; Mirshafiey A
    Biomed Pharmacother; 2018 Apr; 100():495-500. PubMed ID: 29477913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients.
    Aslani M; Ahmadzadeh A; Rezaieyazdi Z; Mortazavi-Jahromi SS; Barati A; Hosseini M; Mirshafiey A
    Recent Pat Inflamm Allergy Drug Discov; 2020; 14(1):69-77. PubMed ID: 31729947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modification of Sexual Hormones in Rheumatoid Arthritis Patients by M2000 (β-D-mannuronic Acid) as a Novel NSAID with Immunosuppressive Property.
    Jahanbakhshi M; Babaloo Z; Mortazavi-Jahromi SS; Shokri MM; Ahmadi H; Mirshafiey A
    Endocr Metab Immune Disord Drug Targets; 2018; 18(5):530-536. PubMed ID: 29667557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapeutic Effects of β-D Mannuronic Acid on IL-4, GATA3, IL-17 and RORC Gene Expression in the PBMC of Patients with Inflammatory Bowel Diseases.
    Alhassan Mohammed H; Saboor-Yaraghi AA; Vahedi H; Panahi G; Hemmasi G; Yekaninejad MS; Mirshafiey A
    Iran J Allergy Asthma Immunol; 2018 Aug; 17(4):308-317. PubMed ID: 30537794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel immunosuppressive therapy by M2000 in experimental multiple sclerosis.
    Mirshafiey A; Matsuo H; Nakane S; Rehm BH; Koh CS; Miyoshi S
    Immunopharmacol Immunotoxicol; 2005; 27(2):255-65. PubMed ID: 16114509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunopharmacological effect of β-d-mannuronic acid (M2000), as a new immunosuppressive drug, on gene expression of miR-155 and its target molecules (SOCS1, SHIP1) in a clinical trial on rheumatoid arthritis patients.
    Mortazavi-Jahromi SS; Aslani M; Omidian S; Ahmadzadeh A; Rezaieyazdi Z; Mirshafiey A
    Drug Dev Res; 2020 May; 81(3):295-304. PubMed ID: 31675124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of M2000 (D-Mannuronic Acid) on Learning, Memory Retrieval, and Associated Determinants in a Rat Model of Alzheimer's Disease.
    Athari Nik Azm S; Vafa M; Sharifzadeh M; Safa M; Barati A; Mirshafiey A
    Am J Alzheimers Dis Other Demen; 2017 Feb; 32(1):12-21. PubMed ID: 28100077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardioprotective effect of β-d-mannuronic acid (M2000) as a novel NSAID on gene expression of oxLDL scavenger receptors in the experimental diabetic model.
    Mortazavi-Jahromi SS; Alizadeh S; Javanbakht MH; Mirshafiey A
    Immunopharmacol Immunotoxicol; 2018 Aug; 40(4):284-289. PubMed ID: 29619884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Effects of Mannuronic Acid on IL-1β, IL-17A, STAT1, and STAT3 Gene Expressions and TLR2 and TLR4 Molecules in Multiple Sclerosis.
    Najafi S; Saadat P; Beladi Moghadam N; Manoucherinia A; Aghazadeh Z; Vali Mohammadi A; Noorbakhsh SM; Movahedi M; Nikouei Moghaddam MR; Pashaiefar H; Mirshafiey A
    J Clin Pharmacol; 2022 Jun; 62(6):762-769. PubMed ID: 34825387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic approach by a novel designed anti-inflammatory drug, M2000, in experimental immune complex glomerulonephritis.
    Mirshafiey A; Rehm B; Sotoude M; Razavi A; Abhari RS; Borzooy Z
    Immunopharmacol Immunotoxicol; 2007; 29(1):49-61. PubMed ID: 17464766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. M2000: a revolution in pharmacology.
    Mirshafiey A; Cuzzocrea S; Rehm BH; Matsuo H
    Med Sci Monit; 2005 Aug; 11(8):PI53-63. PubMed ID: 16049391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-tumor effect of M2000 (β-d-mannuronic acid) on the expression of inflammatory molecules in the prostate cancer cell.
    Mohsenzadegan M; Moghbeli F; Mirshafiey A; Farajollahi MM
    Immunopharmacol Immunotoxicol; 2021 Aug; 43(4):419-430. PubMed ID: 34057866
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of mannuronic acid (M2000) on gene expression profile of signal transducer and activator of transcription proteins (STATs) in rheumatoid arthritis patients.
    Gaafar NAG; Aslani M; Aghazadeh Z; Mortazavi-Jahromi SS; Razavi A; Mirshafiey A
    Reumatismo; 2020 Jul; 72(2):93-102. PubMed ID: 32700875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.